CN110205384B - Spz1的用途及其抑制剂的用途和药物筛选方法 - Google Patents

Spz1的用途及其抑制剂的用途和药物筛选方法 Download PDF

Info

Publication number
CN110205384B
CN110205384B CN201910426342.2A CN201910426342A CN110205384B CN 110205384 B CN110205384 B CN 110205384B CN 201910426342 A CN201910426342 A CN 201910426342A CN 110205384 B CN110205384 B CN 110205384B
Authority
CN
China
Prior art keywords
spz1
gastric cancer
inhibitor
application
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910426342.2A
Other languages
English (en)
Other versions
CN110205384A (zh
Inventor
张鹏
刘晓羽
许键
邱书奇
赵海亮
李红文
曾宪海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen City Longgang District Otolaryngology Hospital
Original Assignee
Shenzhen City Longgang District Otolaryngology Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen City Longgang District Otolaryngology Hospital filed Critical Shenzhen City Longgang District Otolaryngology Hospital
Priority to CN201910426342.2A priority Critical patent/CN110205384B/zh
Publication of CN110205384A publication Critical patent/CN110205384A/zh
Application granted granted Critical
Publication of CN110205384B publication Critical patent/CN110205384B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供一种SPZ1作为靶点在筛选或制备用于预防和/或治疗胃癌的药物中的用途及其抑制剂的用途和对应的筛药方法。转录因子SPZ1与胃癌细胞凋亡密切相关，能间接下调介导胃癌细胞凋亡的Cyclin D1蛋白在胃癌细胞中的表达水平。实验结果表明，SPZ1抑制剂对体内外的胃癌细胞的凋亡有明显促进作用，能够抑制肿瘤生长。因此，本发明为抗胃癌新药的设计提供了新靶点，为抗肿瘤恶性增殖药物的开发和制备提供了新的思路。

Description

SPZ1的用途及其抑制剂的用途和药物筛选方法
技术领域
本发明涉及抗癌技术领域，特别涉及一种SPZ1的用途及其抑制剂的用途和药物筛选方法。
背景技术
胃癌是最常见的癌症类型之一。最新调查数据显示，胃癌是我国最常见的消化系统恶性肿瘤，其发病率和死亡率分别为于第二位和第三位。癌细胞最重要的生物学特征之一是其在体内快速且无限的增殖能力。正常细胞的增殖受自身或微环境的信号所调控，细胞接受足够的信号后才启动增殖程序，但通常认为癌细胞始终处于亢奋的增殖状态。胃癌细胞增殖与凋亡的紊乱是胃癌发生发展的主要原因。因此，研究胃癌细胞增殖的相关机制，寻求有效的抗肿瘤增殖措施进而抑制肿瘤生长进程已成为国内外的研究热点。研究人员发现细胞分裂增殖能力依赖于细胞周期蛋白的调控，而现有的研究结果提示细胞周期蛋白D1(Cyclin D1)的表达增加可能与肿瘤恶性程度密切相关。根据胃癌恶性增殖的产生机制，选择特殊靶点设计研发抗胃癌恶性增殖的药物进行靶向治疗，将对胃癌的治疗非常有益。
SPZ1(spermatogenic leucine zipper1)，即生精亮氨酸拉链蛋白1，属于碱性螺旋-环-螺旋-亮氨酸拉链(basic helix-loop-helix-leucine zipper，bHLH-Zip)结构的一类转录因子，最初发现于小鼠的精子文库之中，功能上与精子生成密切相关，并主要在胚胎发育阶段表达。在转基因鼠和裸鼠模型中，发现活化的SPZ1作为转录因子促进下游基因表达，其中就包括增殖细胞核抗原(proliferating cell nuclear antigen，PCNA)。然而SPZ1与胃癌细胞增殖的相关性还有待进一步的研究。
发明内容
本发明所要解决的一个技术问题在于如何提供一种SPZ1作为靶点在筛选或制备用于预防和/或治疗胃癌的药物中的用途及其抑制剂的用途和对应的药物筛选方法。
本发明所采取的技术方案是：
SPZ1作为靶点在筛选或制备用于预防和/或治疗胃癌的药物中的用途。
根据本发明的实施例，治疗胃癌包括抑制胃癌细胞增殖、促进胃癌细胞凋亡中的至少一种。
SPZ1的抑制剂在制备用于预防和/或治疗胃癌的药物中的用途。
其中，抑制剂是指能够抑制SPZ1发挥功能的物质，其非限制性实例可以是抑制SPZ1相关基因的复制、转录(或转录后修饰)、翻译(或翻译后修饰)的核酸分子、蛋白质或化合物。例如，可以是siRNA、shRNA、dsRNA、miRNA、反义核酸等。
根据本发明的实施例，治疗胃癌包括抑制胃癌细胞增殖、促进胃癌细胞凋亡中的至少一种。
优选的，抑制剂为siRNA、shRNA中的任一种。
优选的，抑制剂为包含shRNA的重组载体或包括该重组载体的重组宿主细胞。
一种预防和/或治疗胃癌的药物或者是抑制胃癌细胞增殖的药物的筛选方法，使用包括SPZ1作为检测靶点进行筛选，其非限制性实例可以是，在筛选过程中进行SPZ1的表达测试以定量SPZ1的表达量。
根据本发明的实施例，治疗胃癌包括抑制胃癌细胞增殖、促进胃癌细胞凋亡中的至少一种。
本发明的有益效果是：
转录因子SPZ1与胃癌细胞凋亡密切相关，能间接下调介导胃癌细胞凋亡的CyclinD1蛋白在胃癌细胞中的表达水平。实验结果表明，SPZ1抑制剂对体内外的胃癌细胞的凋亡有明显促进作用，能够抑制肿瘤生长。因此，本发明为抗胃癌新药的设计提供了新靶点，为抗肿瘤恶性增殖药物的开发和制备提供了新的思路。
附图说明
图1是本发明的一个实施例的Western blot检测结果图。
图2是本发明的一个实施例的细胞增殖实验结果。A是细胞活力检测结果，B是细胞增殖检测结果。
图3是本发明的一个实施例的肿瘤大小结果图。左图是转染Lenti-control(shCTL)和Lenti-SPZ1 shRNA(shSPZ1)慢病毒质粒后的每组各5个重复在第15天取下时的肿瘤照片；右图是不同时间内肿瘤的生长曲线统计图，其中，上侧曲线是shCTL控制组，下侧曲线是shSPZ1实验组。
具体实施方式
以下将结合实施例对本发明的构思及产生的技术效果进行清楚、完整地描述，以充分地理解本发明的目的、特征和效果。
1.实验材料
细胞系：人胃癌细胞AGS，购自美国模式培养物寄存库(ATCC)。
SPZ1抑制剂：SPZ1的siRNA SPZ1#1(其靶向序列为SEQ ID No：1，5′-CCATTGCCTTATTCGAAAT-3′)和siRNA SPZ1#2(其靶向序列为SEQ ID No：2，5′-CCATCAAGTTACAGAACAA-3′)购自广州市锐博生物科技有限公司，SPZ1的抑制性质粒Lenti-SPZ1 shRNA(其靶向序列为SEQ ID No：3，5′-GCTGTCTGAGATGCCACCTTC-3′)购自汉恒生物科技(上海)有限公司。
试剂及试剂盒：CellTiter-Blue Cell Viability Aassay购自美国Promega公司，DharmaFECT 1 Transfection Reagent购自美国GE公司，BrdU Cell Proliferation ELISAkit购自美国Abcam公司，Anti-SPZ1购自美国GeneTex公司，Anti-Cyclin D1购自美国CST公司，Anti-ACTB购自美国Santa Cruz公司。
实验动物：荷瘤小鼠，其制备方法如下：取体外常规培养的AGS细胞，分为两组，一组转染Lenti-SPZ1 shRNA，另一组转染Lenti-control。按照每只小鼠2×106个细胞的接种量接种雄性裸鼠背部。
实验仪器：酶标仪购自美国Molecular Devices公司，5％CO2恒温细胞培养箱购自美国Thermo公司，蛋白电泳仪系统购自美国Bio-Rad公司，蛋白转印仪系统购自美国Bio-Rad公司。
2.实验方法
2.1转染实验
对AGS细胞分别转染siRNA contrl(siCTL)、siRNA SPZ1#1和siRNA SPZ1#2，转染48小时后收集细胞，通过Western blot检测SPZ1与Cyclin的表达量的关系。
2.2体外胃癌细胞抗增殖实验
对AGS细胞分别转染siRNA contrl(siCTL)、siRNA SPZ1#1和siRNA SPZ1#2，转染48小时后收集细胞。应用CellTiter-Blue Cell Viability Aassay检测细胞活力，应用BrdU Cell Proliferation ELISA kit检测细胞增殖。
2.3体内胃癌细胞生长抑制实验
对AGS细胞分别转染Lenti-SPZ1 shRNA和Lenti-control慢病毒质粒。按照每只小鼠2×106个细胞的接种量接种雄性裸鼠背部，15天后取下肿瘤，拍照并测量肿瘤的大小。
3.实验结果
3.1转染实验结果
图1是本发明的一个实施例的Western blot检测结果图。如图1所示，在AGS细胞中，与对照组siCTL相比，SPZ1的两条siRNA均可以显著敲低SPZ1的表达，抑制Cyclin D1的表达。该实验结果表明转录因子SPZ1间接促进细胞周期蛋白Cyclin D1的表达。
3.2体外胃癌细胞抗增殖实验结果
图2是本发明的一个实施例的细胞增殖实验结果。A是细胞活力检测结果，B是细胞增殖检测结果。如图2所示，与对照组相比，转染了SPZ1抑制剂(siRNA SPZ1#1和siRNASPZ1#2)的实验组的AGS细胞的相对存活率和BrdU渗入率都有了显著的下降。这说明，SPZ1抑制剂可以抑制胃癌细胞的细胞活力和增殖能力。该实验结果表明转录因子SPZ1会促进胃癌细胞增殖的发生。
3.3体内胃癌细胞生长抑制实验结果
图3是本发明的一个实施例的肿瘤大小结果图。左图是转染Lenti-control(shCTL)和Lenti-SPZ1 shRNA(shSPZ1)慢病毒质粒后的每组各5个重复在第15天取下时的肿瘤照片；右图是不同时间内肿瘤的生长曲线统计图，其中，上侧曲线是shCTL控制组，下侧曲线是shSPZ1实验组。如图3所示，shSPZ1实验组的肿瘤明显更小，而且生长速度更慢，与对照组相比具有显著性差异，这说明SPZ1抑制剂Lenti-SPZ1 shRNA能明显抑制肿瘤生长。该实验结果表明，SPZ1抑制剂对体内胃癌具有明显的抑制作用，且对实验动物无毒副作用，进一步提示SPZ1抑制剂可为促胃癌凋亡药物的开发和制备提供新的思路。
综合上述实验结果可知，SPZ1的抑制剂对体内和体外的胃癌细胞的凋亡都有明显的促进作用，能够抑制肿瘤生长。因此，本发明为抗胃癌新药的设计提供了新靶点，为抗肿瘤恶性增殖药物的开发和制备提供了新的思路。
显然，以上所描述的实施例仅仅是本发明的一部分实施例，而不是全部的实施例。任何熟悉本技术领域的技术人员在本发明披露的技术范围内，可轻易想到的变化或替换，都应涵盖在本发明的保护范围之内。因此，本发明的保护范围应该以权利要求书的保护范围为准。
SEQUENCE LISTING
<110> 张鹏 深圳市龙岗区耳鼻咽喉医院
<120> SPZ1的用途及其抑制剂的用途和药物筛选方法
<160> 3
<170> PatentIn version 3.5
<210> 1
<211> 19
<212> DNA
<213> 人工序列
<400> 1
ccattgcctt attcgaaat 19
<210> 2
<211> 19
<212> DNA
<213> 人工序列
<400> 2
ccatcaagtt acagaacaa 19
<210> 3
<211> 21
<212> DNA
<213> 人工序列
<400> 3
gctgtctgag atgccacctt c 21

Claims (1)

1. SPZ1的抑制剂在制备用于抑制人胃癌细胞AGS的增殖或生长的药物中的用途，所述抑制剂为siRNA、shRNA中的任一种。
CN201910426342.2A 2019-05-21 2019-05-21 Spz1的用途及其抑制剂的用途和药物筛选方法 Active CN110205384B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910426342.2A CN110205384B (zh) 2019-05-21 2019-05-21 Spz1的用途及其抑制剂的用途和药物筛选方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910426342.2A CN110205384B (zh) 2019-05-21 2019-05-21 Spz1的用途及其抑制剂的用途和药物筛选方法

Publications (2)

Publication Number Publication Date
CN110205384A CN110205384A (zh) 2019-09-06
CN110205384B true CN110205384B (zh) 2023-05-02

Family

ID=67788200

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910426342.2A Active CN110205384B (zh) 2019-05-21 2019-05-21 Spz1的用途及其抑制剂的用途和药物筛选方法

Country Status (1)

Country Link
CN (1) CN110205384B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109223801A (zh) * 2018-08-14 2019-01-18 深圳大学 一种新的胃癌肿瘤干细胞杀伤剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862180A4 (en) * 2005-03-25 2010-09-15 Takeda Pharmaceutical PROPHYLACTIC AND THERAPEUTIC AGENT AGAINST CANCER
CA2525255A1 (en) * 2005-11-03 2007-05-03 Jumi Shin Minimalist bzip proteins and uses thereof
KR100856108B1 (ko) * 2007-02-28 2008-09-02 한국생명공학연구원 Ｚｆｐ91의 활성을 조절하는 분자를 함유하는 항암제,항염증제, 면역질환치료제 또는 허혈성 질환 치료제
CN103937872A (zh) * 2013-01-23 2014-07-23 上海市东方医院 Crm1在胃癌诊断与治疗中的应用
CN107253952B (zh) * 2017-08-01 2019-07-30 烟台大学 具有抗胃癌活性的trpc6抑制剂及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109223801A (zh) * 2018-08-14 2019-01-18 深圳大学 一种新的胃癌肿瘤干细胞杀伤剂及其应用

Also Published As

Publication number Publication date
CN110205384A (zh) 2019-09-06

Similar Documents

Publication Publication Date Title
Bayraktar et al. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase
Daige et al. Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer
Zhou et al. MicroRNA-195 suppresses the progression of pancreatic cancer by targeting DCLK1
Yue et al. Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction
Xiang et al. miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT
Zhang et al. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway
Wu et al. miR‐25 promotes cell proliferation, migration, and invasion of non‐small‐cell lung cancer by targeting the LATS2/YAP signaling pathway
Xu et al. ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma
Huang et al. MiRNA-34a reversed TGF-β-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells
Yang et al. miR-769-5p suppressed cell proliferation, migration and invasion by targeting TGFBR1 in non-small cell lung carcinoma
Zhu et al. TRAF6 promotes the progression and growth of colorectal cancer through nuclear shuttle regulation NF-kB/c-jun signaling pathway
US20140323551A1 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
Qin et al. MiR-200c inhibits the tumor progression of glioma via targeting moesin
Huang et al. micro RNA‐219‐5p inhibits epithelial‐mesenchymal transition and metastasis of colorectal cancer by targeting lymphoid enhancer‐binding factor 1
Liu et al. Extracellular vesicles‐encapsulated let‐7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis
Chen et al. Sox9/INHBB axis-mediated crosstalk between the hepatoma and hepatic stellate cells promotes the metastasis of hepatocellular carcinoma
Hu et al. MCOLN1 promotes proliferation and predicts poor survival of patients with pancreatic ductal adenocarcinoma
Zhou et al. Circ_0006089 promotes gastric cancer growth, metastasis, glycolysis, and angiogenesis by regulating miR‐361‐3p/TGFB1
Wang et al. EGFR‐AS1 promotes bladder cancer progression by upregulating EGFR
Wu et al. WT1‐interacting Protein Inhibits Cell Proliferation and Tumorigenicity in Non‐small‐cell Lung Cancer via the AKT/FOXO1 axis
CN108603194A (zh) 在癌症治疗中用作治疗剂的单羧酸转运蛋白4(mct4)反义寡核苷酸(aso)抑制剂
Chen et al. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR‐488‐3p
Gentilini et al. Extracellular signal‐regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells
Maduri Applicability of RNA interference in cancer therapy: current status
Wu et al. UCP2 silencing in glioblastoma reduces cell proliferation and invasiveness by inhibiting p38áMAPK pathway

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200813

Address after: Shenzhen ENT Hospital, no.3004 Longgang section, Longgang Avenue, Longgang District, Shenzhen City, Guangdong Province

Applicant after: SHENZHEN CITY LONGGANG DISTRICT OTOLARYNGOLOGY Hospital

Address before: 518172 Longgang section, Longgang Avenue, Longgang District, Shenzhen, Guangdong Province, No. 3004 (next to Jixiang station line 3 line), Shenzhen otorhinolaryngology Institute

Applicant before: Zhang Peng

Applicant before: SHENZHEN CITY LONGGANG DISTRICT OTOLARYNGOLOGY Hospital

GR01 Patent grant
GR01 Patent grant